Biomarker for type 1 diabetes
AssigneeThe Trustees of Indiana University
InventorsCarmella EVANS-MOLINA, Farooq SYED
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Trustees of Indiana University
InventorsCarmella EVANS-MOLINA, Farooq SYED
Estimating the term…
In islets collected from female NOD mice at 10, 12, and 14 weeks of age, there was a time-restricted upregulation of proteins involved in the maintenance of β cell function and stress mitigation, followed by loss of expression of these protective proteins that heralded diabetes onset. Pathway analysis showed modulation of EIF2 signaling, the unfolded protein response, mTOR signaling, mitochondrial function, and oxidative phosphorylation during disease progression in NOD mice and in the acute adoptive transfer model, highlighting the importance of this core set of pathways in TID pathogenesis. In immunofluorescence validation studies, β cell expression of protein disulfide isomerase A1 (PDIA1) and 14-3-3b were found to be increased during disease progression in NOD islets, while PDIA1 plasma levels were increased in pre-diabetic NOD mice and in the serum of children with recent-onset TID compared to age and sex-matched non-diabetic controls.
A method of identifying a biomarker associated with early onset type 1 diabetes in humans, said method comprising:
A method for treating subjects at risk for developing type 1 diabetes, the method comprising:
A method for treating subjects at risk for developing type 1 diabetes, the method comprising:
(canceled)
Dependencies are inferred from the claim text.